Immune-dependent antineoplastic effects of cisplatin plus pyridoxine in non-small-cell lung cancer

Fernando Aranda; Normal Bloy; Julien Pesquet; Benoît Petit; Kariman Chaba; Allan Sauvat; Oliver Kepp; Nadine Khadra; David Enot; Christina Pfirschke; Mikaël J. Pittet; Laurence Zitvogel; Guido Guido Kroemer; Laura Senovilla

doi:10.1038/onc.2014.234

Related publications

Article2013

Synergistic interaction between cisplatin and PARP inhibitors in non-small cell lung cancer

Judith Michels, Ilio Vitale, Laura Senovilla, David Enot, Pauline Garcia, Delphine Lissa, Ken A. Olaussen, Catherine Brenner, Jean‐Charles Soria, Maria Castedo, Guido Guido Kroemer

Article2022

PARP1 inhibition elicits immune responses against non-small cell lung cancer

Pan Juncheng, Antoine Lafarge, Guido Guido Kroemer, Maria Castedo

Article1997

164 Treatment of non-small-cell lung cancer. Stages IIIB and IV with docetaxel and cisplatin

V. Georgoulias, N. Androulakis, Meletios A Dimopoulos, C. Kourousis, Stylianos Kakolyris, E. Papadakis, F Apostolopoulou, F. Papadimitriou, A. Vossos, Maria Aggelidou, P. Heras, S. Tzannes, John Souglakos, Dora Hatzidaki

Article2022

Primary and Acquired Resistance against Immune Check Inhibitors in Non-Small Cell Lung Cancer

Qinying Sun, Xiangzhen Wei, Zhong Lin Wang, Yan Zhu, Weiying Zhao, Yuchao Dong

Article2002

Paclitaxel Plus Carboplatin Versus Gemcitabine Plus Paclitaxel in Advanced Non–Small-Cell Lung Cancer: A Phase III Randomized Trial

P. Kosmidis, Nick Mylonakis, C. Nicolaides, C. Kalophonos, Epaminontas Samantas, J. Boukovinas, George Fountzilas, Dimosthenis Skarlos, T. Economopoulos, D. Tsavdaridis, Pavlos Papakostas, C. Bacoyiannis, Meletios A Dimopoulos